SLC5A2 and fatty liver disease: In a study on the population of diabetic individuals in Korea, researchers found that individuals treated with empagliflozin (SGLT2 inhibitors) and/or ezetimibe (a cholesterol absorption inhibitor) had a significantly lower risk of developing fatty liver than those in the untreated reference group.